Clinical Trial Update: Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of Magnevist-enhanced MRA to non-contrast MRA for detecting structural abnormalities in the infrarenal aorta and peripheral ar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Vascular Disease

Drugs mentioned

• Magnevist (gadopentetate dimeglumine)

Snippet

Sponsor: Bayer | Conditions: Peripheral Vascular Disease | Phase 3 | Status: COMPLETED